Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Moderate Buy” by Analysts

Precigen, Inc. (NASDAQ:PGEN) has earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.00.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Precigen in a research note on Friday, November 15th.

Precigen Stock Up 5.2 %

Shares of NASDAQ PGEN opened at $0.79 on Thursday. Precigen has a 52 week low of $0.65 and a 52 week high of $1.93. The firm has a market cap of $229.96 million, a P/E ratio of -1.43 and a beta of 1.71. The business’s 50 day moving average price is $0.84 and its 200 day moving average price is $1.12.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PGEN. Traphagen Investment Advisors LLC purchased a new position in Precigen in the 3rd quarter valued at $29,000. Stifel Financial Corp grew its stake in Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares in the last quarter. SG Americas Securities LLC raised its holdings in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 13,823 shares during the last quarter. AQR Capital Management LLC lifted its stake in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Precigen by 86.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 25,681 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.